Novo Nordisk A/S (NYSE:NVO) Shares Sold by UMB Bank n.a.

UMB Bank n.a. trimmed its holdings in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 1.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,385 shares of the company’s stock after selling 410 shares during the period. UMB Bank n.a.’s holdings in Novo Nordisk A/S were worth $3,165,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Perigon Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Perigon Wealth Management LLC now owns 2,603 shares of the company’s stock valued at $259,000 after purchasing an additional 80 shares in the last quarter. SRS Capital Advisors Inc. raised its position in shares of Novo Nordisk A/S by 9.8% in the 3rd quarter. SRS Capital Advisors Inc. now owns 985 shares of the company’s stock valued at $98,000 after purchasing an additional 88 shares in the last quarter. RFG Advisory LLC raised its position in shares of Novo Nordisk A/S by 2.6% in the 3rd quarter. RFG Advisory LLC now owns 3,681 shares of the company’s stock valued at $423,000 after purchasing an additional 92 shares in the last quarter. Kolinsky Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 2.6% in the 3rd quarter. Kolinsky Wealth Management LLC now owns 3,647 shares of the company’s stock valued at $363,000 after purchasing an additional 94 shares in the last quarter. Finally, Csenge Advisory Group raised its position in shares of Novo Nordisk A/S by 3.9% in the 3rd quarter. Csenge Advisory Group now owns 2,542 shares of the company’s stock valued at $253,000 after purchasing an additional 95 shares in the last quarter. 6.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVO has been the topic of several research reports. JPMorgan Chase & Co. upped their price target on Novo Nordisk A/S from 925.00 to 1,100.00 and gave the company an “overweight” rating in a research report on Tuesday, January 3rd. Cowen upped their price target on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. StockNews.com initiated coverage on Novo Nordisk A/S in a research report on Thursday. They set a “strong-buy” rating on the stock. Finally, Cowen upped their price target on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $697.78.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $139.44 on Friday. The company has a market cap of $315.55 billion, a P/E ratio of 40.18, a PEG ratio of 1.47 and a beta of 0.47. The stock has a fifty day moving average price of $139.97 and a 200 day moving average price of $123.57. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.89 and a quick ratio of 0.69. Novo Nordisk A/S has a 12 month low of $95.02 and a 12 month high of $145.94.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 4th. Investors of record on Monday, March 27th will be paid a dividend of $1.1887 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.58. This represents a yield of 0.8%. The ex-dividend date of this dividend is Friday, March 24th. Novo Nordisk A/S’s dividend payout ratio is presently 23.34%.

About Novo Nordisk A/S

(Get Rating)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.